Momentis Announces First Adoption of Anovo™ Surgical System in Texas by Medical City Plano

Momentis Surgical™ Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that Medical City Plano has acquired the Anovo™ Surgical System for use in transvaginal benign gynecological procedures including benign hysterectomies. Medical City Plano is the first medical facility in Texas to adopt this system.

The Anovo System is the first and only FDA-authorized surgical robot that features miniature humanoid-shaped arms, with shoulder, elbow, and wrist joints that mimic a surgeon’s precise movements for high agility and dexterity. It is designed to enable the minimally invasive transvaginal approach for benign gynecological procedures including hysterectomy, salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal. Anovo is designed to enable surgeons to use the transvaginal approach in gynecological procedures, which has been well documented in clinical research as providing benefits including less patient pain and scarring, shorter recovery times and reduced infection rates, compared to other approaches.[i]

The Anovo System also requires a much smaller footprint and costs significantly less than conventional robotic systems, making it possible for more hospitals and ambulatory surgery centers to acquire the system and offer more patients the benefits of less invasive robotic surgery.

“Incorporating a smaller, lighter, and more cost effective robotic surgical platform will allow more rural areas, smaller hospitals and surgery centers to offer minimally invasive surgery, resulting in more patients having access to the most up-to-date and least invasive surgical options. We are proud to be the first in Texas to adopt this remarkable new technology and make it available to patients,” said Thomas P. Heffernan, MD, a practicing gynecologic oncologist at Medical City Plano.

“We are pleased to see significant progress in bringing the Anovo Surgical System, the first surgical robot of its kind, to more healthcare facilities and patients across the U.S. including acute care hospitals such as Medical City Plano,” said Dvir Cohen, CEO and Co-Founder of Momentis. “In the months ahead, we will continue our efforts to broaden availability of the system and improve gynecological surgery to enable more surgeons to perform the clinically preferred transvaginal approach, setting a higher standard in women’s healthcare.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version